The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer
about
HER2/neu in systemic therapy for women with breast cancer: a systematic review.S-phase fraction and breast cancer--a decade of experience.Role of HER2 gene overexpression in breast carcinoma.Testing for HER2 in Breast Cancer: A Continuing Evolution.The significance of immunohistochemistry in the diagnosis and therapy of neoplasms.Endocrine therapy for advanced breast cancer: a review.The polymerase chain reaction: its use in the molecular characterization and diagnosis of cancers.Targeted therapy in breast cancer: the HER-2/neu gene and protein.Prognostic significance of c-erbB-2 expression in node negative breast cancerHormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens.Prostatic carcinoma: a multivariate analysis of prognostic factors.c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis.Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.Breast and prostate cancer.Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.Hormone Receptors, Her-2/Neu and Chromosomal Aberrations in Breast CancerSynthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.Prognostic association of c-erbB-2 oncogene amplification and protein overexpression in human breast cancer using archival tissues. A comparative study.Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study.Prognostic significance of oncogenes and tumor suppressor genes in human malignancy.Biological indices in the assessment of breast cancer.Expression of c-erbB-2 protein in papillary thyroid carcinomas.c-erbB-2 oncogene as a prognostic marker in breast cancer.Type 1 protein tyrosine kinases in Chinese breast carcinomas: a clinicopathologic study.Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.C-erbB-2 overexpression and survival in early onset breast cancer.Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor.The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer.Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression.Adjuvant trastuzumab in breast cancer: experience from the University of Florence.Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.Construction of immunoradiometric assay for circulating c-erbB-2 protooncogene product in advanced breast cancer patients.
P2860
Q33291068-2F5734DE-29A2-4C62-8BD6-895BCF3D9FE1Q33539158-1CCEF5BC-3D45-4460-B30A-EA75CB5FD0EFQ33810080-C55BCAD3-4A99-4445-9E8A-B70094A43FF1Q34424285-8BBFA314-E32D-4DF3-BA4F-89A45C64DECEQ34602545-A1597866-410F-4F90-A82C-C8B7FE459608Q35338479-7939BD58-F617-481D-A89E-42A4415B1335Q35367235-B416D1FE-0560-4A94-9A4D-01C1821EDF9CQ35648508-6DAF3E70-E333-4852-A150-19B8856BA887Q35976044-6BE62A1E-4885-401B-8A1E-92CEFDF211A3Q35977233-EB6528F8-066B-4E40-9B97-9310A24294BFQ35978450-82634442-BFF2-42DA-B760-AF95EE71F545Q35993223-7663FECD-E635-4910-A3B2-4DA536A8AAFFQ36081269-236090AD-BE60-49E9-9993-B3CBFDF5991FQ36265549-50061D52-BF43-40CC-B20A-5139BBE355C7Q36696088-2AE8CEB3-14E7-4425-A5B6-17B0893CBECCQ37039674-A1AA3330-EE4D-4E3B-92CF-D89BBBDF4C7DQ37280359-B9052420-9601-4100-9734-8658A7FFC3E0Q38484552-D2621A4D-A0C8-4391-818C-66BAFCF66CAEQ40735449-E7BC9D69-00E0-4CB4-819E-C85B396086E0Q40819584-D065C259-9143-4D6B-BD61-990934B8E1BFQ40848953-12BB6EF6-E6F9-4624-98B3-F6E77DAB83F6Q42372015-1263F9F6-F71C-4A65-8261-F4E6843F7925Q42383432-A7E114A1-DBBA-4C2C-B27A-3EB9E253EABEQ43754966-173589AA-F093-4BD5-9FA9-5F5F4F73E6A7Q43759908-996D2285-C9DF-4D3F-912D-168B52F2AD56Q43882782-357E74C2-71F7-4ECA-8E6B-21992299BC10Q43982351-9B4B565E-2F5D-417B-BD33-9CDC41D9314CQ48123892-FCE14A56-29DD-45EB-A015-B6827FCF3943Q51155024-90C94EA5-66FB-4547-BD57-A7DA81EF8B12Q51772826-44B15DB8-4413-447E-B147-523CFF9F1AB9Q53465230-F99076F3-8FAA-4186-917F-8FA2034A1EF1Q54115075-46F6CE9F-BA83-49FB-A1F4-DF5EDB2A44B6Q55194670-BA984D31-1D76-4C6A-831A-0DFB0491701C
P2860
The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
The relationship between c-erb ...... and prognosis in breast cancer
@ast
The relationship between c-erb ...... and prognosis in breast cancer
@en
type
label
The relationship between c-erb ...... and prognosis in breast cancer
@ast
The relationship between c-erb ...... and prognosis in breast cancer
@en
prefLabel
The relationship between c-erb ...... and prognosis in breast cancer
@ast
The relationship between c-erb ...... and prognosis in breast cancer
@en
P2093
P2860
P356
P1476
The relationship between c-erb ...... and prognosis in breast cancer
@en
P2093
Bartkova J
Camplejohn RS
Gregory WM
O'Reilly SM
Richards MA
P2860
P2888
P304
P356
10.1038/BJC.1991.102
P407
P577
1991-03-01T00:00:00Z